Combination of PARP inhibitor and temozolomide to suppress chordoma progression

Chordoma, a malignant bone cancer, is highly resistant to conventional therapeutic approaches; this greatly limits radio- and chemotherapeutic options and disease management. In the present study, we investigated three patient-derived chordoma cell lines to elucidate the molecular mechanism of resis...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Mol Med (Berl)
Main Authors: Cao, Xiaoyu, Lu, Yanxin, Liu, Yang, Zhou, Yiqiang, Song, Hua, Zhang, Wei, Davis, Dionne, Cui, Jing, Hao, Shuyu, Jung, Jinkyu, Wu, Qixin, Park, Deric M., Yang, Chunzhang
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323588/
https://ncbi.nlm.nih.gov/pubmed/31201471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00109-019-01802-z
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki